Introduction
============

*Acinetobacter baumannii* is an important opportunistic pathogen associated with a variety of nosocomial infections, such as ventilator-associated pneumonia, central line-associated bloodstream infections, urinary tract infections, surgical-site infections, and other types of wound infections, especially in intensive care units (ICUs; [@B22]). This organism is well adapted to hospital environments, being capable of continually spreading to new patients and making itself a nosocomial pathogen of particular clinical concern and a public health threat ([@B4]).

In recent years, multidrug-resistant *A. baumannii* (MDR-AB) isolates have been increasingly reported worldwide. MDR-AB strains are associated with an enhanced risk of mortality and prolonged durations of hospitalization ([@B13]; [@B2]; [@B16]). Carbapenems, mainly imipenem (IPM) and meropenem (MPM), have been used to treat MDR-AB infections ([@B23]). However, the incidence of carbapenem resistance in *A. baumannii* is growing steadily in China and many other countries ([@B26]; [@B31],[@B32]). According to the CHINET 2010 year reports, the resistant to IPM and MPM in *A. baumannii* isolates was 62.3% and 63.8%, respectively ([@B37]). However, few data are available regarding the molecular epidemiology and antibiotic resistance of *A. baumannii* infections in hospitals in Beijing, China.

The accurate and rapid identification of *A. baumannii* is critical for appropriate infection control in hospital settings. To date, the most common and widespread detection methods include characterization via a phenotypic system and commercial phenotypic methods (e.g., the VITEK 2 system \[Biomerieux\] and the API 20 NE system) or DNA-based testing such as PCR (e.g., 16S rRNA gene amplification), which have been used to successfully identify most *Acinetobacter* species. However, there are some limitations in these methods ([@B10]; [@B12]; [@B1]). For example, several days are needed for incubation, and the laboratory diagnosis of *A. baumannii* is actually for that of the *A. calcoaceticus*--*A. baumannii* complex (ABC), which includes *A. calcoaceticus*, *A. baumannii*, *A. pittii* (three species), and *A. nosocomialis* (species 13TU; [@B22]). These bacterial species are different in terms of symptomatology, dissemination patterns, mechanisms of antibiotic resistance, and epidemiology ([@B8]; [@B3]).

The loop-mediated isothermal amplification (LAMP) method, which is based on autocycling strand displacement DNA synthesis in the presence of Bst DNA polymerase, can be used to amplify target DNA with high specificity (as four or six specific primers that recognize six or eight different sequences on the DNA target) under isothermal conditions in less than 60 min ([@B19]). LAMP is highly sensitive and able to detect DNA at as few as six copies in the reaction mixture, and less prone to the presence of irrelevant DNA than PCR ([@B19]). This novel method has been developed widely for the detection of numerous pathogens, including influenza A subtypes H1N1 ([@B18]), H5N1 ([@B5]), H7N9 ([@B17]), as well as *Mycoplasma pneumoniae* ([@B9]), *Mycobacterium tuberculosis* ([@B14]), severe acute respiratory syndrome virus coronavirus ([@B27]), and human immunodeficiency virus ([@B41]).

In present study, we describe a LAMP method for the rapid detection of *A. baumannii* in clinical samples targeting the *bla*~OXA-51~ gene, which was based on visual testing. We also investigated molecular-epidemiology and antibiotic-resistance profiles, and detected several common oxacillinase genes from *A. baumannii* isolates obtained at two comprehensive hospitals in Beijing, China.

Materials and Methods {#s1}
=====================

Bacterial Strains, Antimicrobial Susceptibility Testing, and Pulsed-Field Gel Electrophoresis (PFGE)
----------------------------------------------------------------------------------------------------

A total of 34 strains representing 9 *Acinetobacter* species (2 *A. baumannii* strains and 10 other *Acinetobacter* strains) and 22 non-*Acinetobacter* species used in this study to develop the LAMP assays. Three hundred and fifty-five clinical sputum samples and nasopharyngeal swabs were obtained from the ICU hospitalized patients with clinically suspected multi-resistant infections in 307th (Affiliated Hospital of Academy of Military Medical Sciences), and the 309th Hospital of PLA in China. Pertinent information and the source of all strains are listed in **Table [1](#T1){ref-type="table"}**. The species identification were identified by the Vitek 2 system (Biomerieux Vitek, Inc., Hazelwood, MO, USA). *A. baumannii* bacteria were grown overnight at 37°C in Luria-Bertani (LB) broth, while non-*Acinetobacter* species were cultured at 37°C in brain heart infusion (BHI) broth overnight.

###### 

Bacteria strains used in this study.

  Bacteria strains                                    Source                                     Strain type
  --------------------------------------------------- ------------------------------------------ ------------------
  ***Acinetobacter* species**                                                                    
  *A. baumannii*                                      CGMCC                                      Reference strain
  *A. baumannii* ATCC 22933                           CICC                                       Reference strain
  *A. calcoaceticus*                                  CGMCC                                      Reference strain
  *A. nosocomialis*                                   CGMCC                                      Reference strain
  *A. haemolyticus*                                   CGMCC                                      Reference strain
  *A. Pittii*                                         CICC                                       Reference strain
  *A. johnsonii*                                      CGMCC                                      Reference strain
  *A. junii*                                          CGMCC                                      Reference strain
  *A. calcoaceticus*                                  The Microorganism Center^a^                Reference strain
  *A. lwoffii*                                        The Microorganism Center (three strains)   Reference strain
  **Non-*Acinetobacter* species**                                                                
  *Bacillus megatherium* 4623                         The Microorganism Center                   Reference strain
  *Beta-haemolytic streptococcus* group A CMCC32213   The Microorganism Center                   Reference strain
  *Bordetella pertussis* ATCC 18530                   The Microorganism Center                   Reference strain
  *Brucella suis* 3572                                The Microorganism Center                   Reference strain
  *Corynebacterium diphtheria* CMCC38001              The Microorganism Center                   Reference strain
  *Enteropathogenic Escherichia coli* 2348            The Microorganism Center                   Reference strain
  *Enterotoxigenic E. coli* 44824                     The Microorganism Center                   Reference strain
  *E. coli* ATCC25922                                 The Microorganism Center                   Reference strain
  *Mycobacterium tuberculosis* 8362                   The Microorganism Center                   Reference strain
  *Neisseria meningitides* group B CMCC29022          The Microorganism Center                   Reference strain
  *Pseudomonas aeruginosa* ATCC27853                  The Microorganism Center                   Reference strain
  *Salmonella aberdeen* 9264                          The Microorganism Center                   Reference strain
  *Salmonella enteritidis* 50326-1                    The Microorganism Center                   Reference strain
  *Stenotrophomonas maltophilia* 3859                 The Microorganism Center                   Reference strain
  *Shigella flexneri* 4536                            The Microorganism Center                   Reference strain
  *Shigella sonnei* 2531                              The Microorganism Center                   Reference strain
  *Staphylococcus aureus* 2740                        The Microorganism Center                   Reference strain
  *Vibrio carchariae* 5732                            The Microorganism Center                   Reference strain
  *Vibrio cholera* 3802                               The Microorganism Center                   Reference strain
  *Vibrio parahaemolyticus* 5474                      The Microorganism Center                   Reference strain
  *Yersinia enterocxolitica* 1836                     The Microorganism Center                   Reference strain
  *Yersinia pestis* 2638                              The Microorganism Center                   Reference strain

CGMCC, China General Microbiological Culture Collection Center; CICC, China Center of Industrial Culture Collection.

a

The Microorganism Center of the Institute of Disease Control and Prevention of the Academy of Military Medical Sciences

.

Antibiotic susceptibility testing was conducted by disk diffusion in accordance with the guidelines of the Clinical and Laboratory Standards Institute and was confirmed by the Vitek 2 System with the following antibiotics: ampicillin, ampicillin/sulbactam, aztreonam, ciprofloxacin, ceftazidime, ceftriaxone, cefepime, gentamycin, levofloxacin, IPM, MPM, piperacillin/tazobactam, piperacillin, tobramycin, and sulfamethoxazole. *Pseudomonas aeruginosa* ATCC 27853 was used as a control.

Genomic DNA was prepared in agarose plugs, and digested with the restriction enzyme *Apa*I (New England BioLabs, Beverly, MA, USA). The DNA restriction fragments were separated using a CHEF-DRIII apparatus (Bio-Rad Laboratories, Richmond, CA, USA). Gel images were analyzed using BioNumerics software, version 6.01 (Applied-Maths, Belgium). The interpretation of gels was performed by visual inspection using the criteria of [@B30].

Preparation of Isolated DNA
---------------------------

Genomic DNA from *Acinetobacter* species was prepared using the boiling method described by [@B20], with some modifications. Briefly, colonies of each isolate were picked from LB plates and suspended in 100 μl of ddH~2~O. The bacterial suspensions were boiled at 95°C for 15 min, centrifuged at 12,000 rpm for 5 min, and the supernatants were collected and transferred to fresh Eppendorf tubes as templates for use in LAMP and PCR assays. To determine the sensitivity and specificity of the LAMP assays, bacterial genomic DNA was extracted from *A. baumannii* using the Wizard^®^ Genomic DNA Purification Kit A1125 (Promega, Madison, WI, USA). The DNA concentration was measured by using OD260 measurements (ND-1000 spectrophotometer, NanoDrop Technologies, Inc, Wilmington, DE, USA) and prepared by serial 10-fold dilutions to yield concentrations ranging from 500 ng/μl to 0.05 pg/μl.

Primer Design for LAMP Assay
----------------------------

The sequence of *bla*~OXA-51~ (GenBank No. DQ385606.1) was downloaded from the NCBI GenBank database and used to design *bla*~OXA-51~-specific LAMP primers. The sequence was further analyzed by Primer Explorer software (version 4; <http://www.primerexplorer.jp/lamp/>), and five sets of primers were designed, including the outer forward primer (F3), the outer backward primer (B3), the forward inner primer (FIP), the backward inner primer (BIP), and additional loop primers (loops F and B), as shown in **Table [2](#T2){ref-type="table"}**.

###### 

Sequence of primers used for specific amplification of *bla*~OXA-51-like~ and the OXA carbapenemases PCR detection.

  Primer                 Primer type      Sequence (5′--3′)
  ---------------------- ---------------- --------------------------------------------------
  OXA-4F3                Forward outer    CTTATATAGTGACTGCTAATCCAA
  OXA-4B3                Backward outer   ATTAAGCATTTTGAAGGTCGA
  OXA-4FIP               Forward inner    ACCCGTAGTGTGTACTTCGTTAAATTTTTACAGCGCTTCAAAATCTGA
  OXA-4BIP               Backward inner   TTAGTTATCCAACAAGGCCAAACTTTTTAGCAGGTACATACTCGGTC
  OXA-4LB                Loop forward     AAAGCTATGGTAATGATCTTGCTCG
  *bla*~OXA-23-F~        Forward          ATGAATAAATATTTTACTTG
  *bla*~OXA-23-R~        Reverse          TTAAATAATATTCAGCTGTT
  *bla*~OXA-24-F~        Forward          ATGAAAAAATTTATACTTCCTATATTCAGC
  *bla*~OXA-24-R~        Reverse          TTAAATGATTCCAAGATTTTCTAGC
  *bla*~OXA-51-like-F~   Forward          TAATGCTTTGATCGGCCTTG
  *bla*~OXA-51-like-R~   Reverse          CTATAAAATACCTAATTKTTCTAA
  *bla*~OXA-58-F~        Forward          ATGAAATTATTAAAAATATTGAGT
  *bla*~OXA-58-R~        Reverse          ATAAATAATGAAAAACACCCAA

LAMP Reaction and Product Detection
-----------------------------------

LAMP reactions were performed in a total volume of 25 μl and contained 12.5 μl reaction mixtures (DNA Amplification Kit; Eiken Chemical Co., Ltd., Tochigi, Japan), 2.6 μl primer mixture (40 pmol for FIP and BIP, 20 pmol for LF and LB, and 5 pmol for F3 and B3), and 1 μl of *Bst* polymerase (eight units, New England BioLabs, Ipswich, MA, USA). Finally, 1-μl DNA of genomic template DNA (the concentration is above 50 ng/μl) was added to the reaction tubes. Reaction was performed in a LA-320CE instrument (Eiken Chemical Co., Ltd., Tochigi, Japan) at 65°C for 60 min and stopped by heating to 80°C for 5 min, according to the manufacturer's instructions. The LA-320CE instrument can monitor the turbidity of real-time LAMP products through spectrophotometric analysis by recording the optical density at 650 nm every 6 s with the help of a Loopamp real-time turbidimeter. In addition, a visual color-change detection method was employed. Briefly, 1 μl of fluorescence-detection reagent (Eiken Chemical Co., Ltd., Tochigi, Japan) was added to each 25 μl LAMP-reaction mixture prior to initiating the reactions. Positive reactions were identified by a green color change, while negative reactions remained orange in color. The color change could be observed by the naked eye under natural light, or with the aid of ultraviolet light excitation at 365 nm.

To compare the sensitivity and specificity of LAMP with PCR, normal PCR reactions were performed using the *bla*~OXA-51-like-F~ and *bla*~OXA-51-like-R~ primers (**Table [2](#T2){ref-type="table"}**). The primers were synthesized commercially by Sangon Biotech Co., Ltd. (Beijing, China). PCR was performed as described previously ([@B15]).

PCR Detection of Carbapenemase Genes
------------------------------------

The class D OXA carbapenemases of *Acinetobacter* sp. are represented by 4 main phylogenetic subgroups: OXA-23-like, OXA-24-like, OXA-51-like, and OXA-58. The primers used for detecting these genes by PCR are listed in **Table [2](#T2){ref-type="table"}**. PCR was performed in a 25-μl reaction mixtures containing 12.5 μl PCR Master Mix Reagent (Tiangen Biotech Co., Ltd., Beijing, China); 1 μl of forward primer (10 pmol), 1 μl of reverse primer (10 pmol), and 1 μl of DNA template. Reaction mixtures were initially heated to 94°C for 5 min, followed by 30 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 90 s. The final extension step was performed at 72°C for 7 min. The PCR-amplified products were analyzed by 1% agarose gel electrophoresis and stained with ethidium bromide. Images were acquired using a Bio-Rad Gel Doc EQ imaging system.

Results
=======

Optimization of the LAMP Assay Targeting *bla*~OXA-51-like~
-----------------------------------------------------------

Five sets of different primers were initially tested for detection of the *bla*~OXA-51-like~ gene, and the primers for *pga*D gene of *A. baumannii* were added as a control ([@B35]). Four of the five primer sets enabled successful amplification (**Figure [1](#F1){ref-type="fig"}**). The OXA-4 primer set amplified the target sequence within the shortest time and was, therefore, chosen as the optimal primer set (**Table [2](#T2){ref-type="table"}**).

![**Five sets of primers were used to amplify the indicated target genes of *Acinetobacter baumannii* under the same conditions**. Turbidity was monitored using a Loopamp real-time turbidimeter by measuring the absorbance at 650 nm every 6 s. The OXA-4 primer set was chosen as the most appropriate primers for the rapid detection of *A. baumannii.*](fmicb-06-00997-g001){#F1}

Reaction temperatures ranging from 55 to 69°C at a 2°C intervals were compared to determine optimal amplification conditions. The amplification efficiency was highest at 65°C (**Figure [2](#F2){ref-type="fig"}**) and was, therefore, used in subsequent experiments.

![**Effect of differing temperatures on the efficiency of detection of *A. baumannii* by loop-mediated isothermal amplification (LAMP)**. Turbidity was monitored using a Loopamp real-time turbidimeter by measuring the absorbance at 650 nm every 6 s.](fmicb-06-00997-g002){#F2}

Specificity and Sensitivity of the LAMP Assay
---------------------------------------------

To evaluate the specificity of LAMP detection for *A. baumannii*, genomic DNA was extracted from 2 *A. baumannii* strains, as well as other 7 *Acinetobacter* species (10 strains) and 22 non-*A. baumannii* reference strains, and tested using real-time turbidity or visual detection of color changes as readouts. Genomic *A. baumannii* DNA (ATCC 22933) and distilled water were used as positive and negative controls, respectively. As shown in **Figure [3](#F3){ref-type="fig"}**, both methods of analysis positively identified the *A. baumannii* isolates. All other strains (as well as the blank control) tested negatively, indicating that the LAMP assay was specific for *A. baumannii*. Interestingly, the LAMP assay could differentiate *A. baumannii* from other *Acinetobacter* species.

![**Specificity of the LAMP reactions in detecting the *bla*~OXA-51-like~ gene**. Turbidity was monitored using a Loopamp real-time turbidimeter by measuring the absorbance at 650 nm every 6 s. Amplification was performed at 65°C for 60 min.](fmicb-06-00997-g003){#F3}

To compare the detection limit of traditional PCR with that of LAMP using either real-time turbidity or color-change measurements, 10-fold serial dilutions (50 ng/μl--5 pg/μl) were tested using genomic DNA extracted from *A. baumannii* ATCC 22933. As shown in **Figure [4](#F4){ref-type="fig"}**, the detection limits of real-time turbidity and visual detection were both 50 pg/μl, which was 10-fold more sensitive than traditional PCR assay.

![**Sensitivity of the LAMP reaction and PCR for detection of the *bla*~OXA-51-like~ gene**. Genomic DNA was diluted in a set of serial 10-fold dilutions. Both LAMP reactions **(A,B)** and PCR **(C)** were performed in duplicate for each dilution. Tubes and lanes: 1: 500 ng/μl, 2: 50 ng/μl, 3: 5 ng/μl, 4: 500 pg/μl, 5: 50 pg/μl, 6: 5 pg/μl, 7: 0.5 pg/μl, 8: 0.05 pg/μl. **(A)** Turbidity was monitored using a Loopamp real-time turbidimeter by measuring the absorbance at 650 nm every 6 s. **(B)** The direct visual method for the detection of LAMP. One microliter of fluorescent detection reagent was added to 25 μl of LAMP reaction mixture before the LAMP reactions were initiated. **(C)** PCR products were separated by 1% agarose gel electrophoresis and stained with ethidium bromide.](fmicb-06-00997-g004){#F4}

Detection of *A. baumannii* in Clinical Samples
-----------------------------------------------

A total of 355 clinical sputum samples and nasopharyngeal swabs were collected for LAMP-based surveillance of *bla*~OXA-51-like~ from ICU patients suspected of having multidrug-resistant infections in two hospitals in Beijing, China. Ten pairs of sputum samples and nasopharyngeal swabs from healthy people were collected as controls. All clinical samples were simultaneously analyzed by LAMP and PCR. Of the 355 clinical samples, the LAMP assay detected 228 positive samples and 127 negative samples, while the PCR assay detected 221 positive samples, and 134 negative samples. Then, *A. baumannii* was successfully cultured from all 228 samples that were positively identified by LAMP. Samples from the healthy control subjects all tested negatively by LAMP and PCR. The LAMP assay showed 100% specificity compared to 91.89% by PCR assay. Thus, the results showed the LAMP assays were more sensitive and specific than PCR for the diagnosis of *A. baumannii* in clinical samples.

Antibiotic Susceptibility and Oxacillinase Distribution
-------------------------------------------------------

A total of 228 clinical *A. baumannii* isolates were characterized by antibiotic susceptibility testing using both the VITEK^®^2 system and disk diffusion. Resistance rates were very high, with nearly 90% isolates being resistant to ampicillin, 68.2% being MDR-AB, 66.5% being resistant to IPM, and 63.6% being resistant to MPM.

Among all 145 isolates resistant to both IPM and MPM, 100% harbored the *bla*~OXA-51-like~ gene, 92.3% (134 strains) co-occurred with the *bla*~OXA-23~ gene, 1 isolate carrying both the *bla*~OXA-51-like~ gene and *bla*~OXA-58~ gene, and no isolate carried the *bla*~OXA-24~ gene. Ten isolates were negative for the tested plasmid-mediated OXA-carbapenemase genes.

We also investigated the presence of the *bla*~OXA-51-like~ gene in *A. baumannii* isolates susceptible to carbapenem treatment. All of these isolates harbored the naturally occurring *bla*~OXA-51-like~ gene, making it an excellent candidate for the identification of *Acinetobacter* species.

Molecular Epidemiology of Carbapenem-Resistant *A. baumannii*
-------------------------------------------------------------

Forty-one out of 145 carbapenem-resistant *A. baumannii* isolates were analyzed by PFGE. Genomic DNA digested with *Apa*I showing similar patterns were designated as the same type, and those with 1--3 different bands compared with this type were designated as subtypes. Digested DNA with \>3 different bands compared with one type were designated as other types. Bionumerisc software V6.01 was used to perform cluster analysis of these data.

A total of 33 PFGE-banding types were identified, suggesting a diverse population of *A. baumannii* rather than the spread of a specific clone. According to the dice similarity index (80%), these types could be clustered into eight distinct PFGE patterns (clones A--H), and clone C was the dominant clone with 24 isolates (**Figure [5](#F5){ref-type="fig"}**). Clinical isolates with PFGE-banding type 18 (PF-18) represented the dominant epidemic strain in the ICU during the testing period.

![**Pulsed-field gel electrophoresis (PFGE) of *Apa* I-digested DNA from 41 *A. baumannii* isolates**. The dendrogram shown was generated via the unweighted pair-group method using arithmetic averages approach, based on Dice similarity coefficients that were determined using BioNumerics software, V6.01.](fmicb-06-00997-g005){#F5}

Discussion
==========

Carbapenems including IPM and MPM are used as a last resort for treating MDR-AB. The incidence of carbapenem resistance in *A. baumannii* has increased steadily over the past decade and now represents a global problem. The Meropenem Yearly Susceptibility Test Information Collection program revealed a considerable worldwide increase in IPM and MPM resistance rates, which increased from 10 and 35% in 1999 to 47.9 and 57.4% in 2008, respectively ([@B28]). Similarly, the SENTRY program documented an overall increase in IPM resistance from 34.5% in 2006 to 59.8% in 2009 ([@B7]). In the USA and Europe, carbapenem resistance accounted for 65% of *A. baumannii*-related pneumonia in 2012 ([@B6]). In Asia, more than 60% of *A. baumannii* isolates causing hospital-acquired pneumonia were pan-resistant bacteria and resistant to carbapenem ([@B39]; [@B33]).

In this study, we observed that 66.5% (152 strains) or 63.6% (145 strains) of test isolates were resistant to IPM or MPM, respectively. The 228 clinical *A. baumannii* isolates were mainly collected from the ICUs of two hospitals; thus, the incidence of carbapenem resistance in *A. baumannii* was relatively high. Prolonged hospitalization, invasive medical procedures, and the prior use of broad-spectrum antibiotics (third-generation cephalosporins and fluoroquinolones) are risk factors for the acquisition of MDR-AB ([@B11]). These findings indicated that treatment with carbapenem may potentially induce carbapenem resistance.

During PFGE analysis, 33 PFGE-banding patterns were identified and classified into 8 distinct clones, based on Tenover's criteria ([@B30]). Clone C was the dominant clone, making it possibly responsible for the *A. baumannii* epidemic in the ICUs of the two comprehensive hospitals from which we obtained the isolates. Clinical isolates of subtype PF-18 represented the main epidemic strain during the testing period. Previous results have demonstrated that carbapenem-resistant *A. baumannii* isolates showing the same PFGE patterns possess the same carbapenemase-associated genes ([@B38]; [@B21]); however, our results were not consistent with these observations. Three isolates carrying only the *bla*~OXA-51-like~ gene, but not the *bla*~OXA-23~ gene, were grouped into different clones. However, isolates carrying both the *bla*~OXA-51-like~ gene and the *bla*~OXA-23~ gene were clustered into distinct clones, either. This may be due to the complicated resistance mechanism that underlies carbapenem resistance in *A. baumannii*.

Carbapenem susceptibility in *A. baumannii* is compromised by a variety of mechanisms. By far the most common mechanism are carbapenemases ([@B24]). Carbapenem-hydrolyzing class D β-lactamases (CHDLs, Ambler class D), also known as oxacillinases, are the most common mediator of carbapenem resistance in *A. baumannii* ([@B26]), although they are relatively inefficient compared with other types of carbapenemases, such as class B metallo-β-lactamases (MBLs; Ambler class B) represented by the VIM, IMP, SIM families, and the recently discovered New Delhi metallo-β-lactamase (NDM).

Among CHDLs in *A. baumannii*, there are four major distinct groups, including OXA-23, OXA-24, OXA-51-like, and OXA-58, which are encoded by the *bla*~OXA-23~, *bla*~OXA-24~, *bla*~OXA-51-like~, and *bla*~OXA-58~ genes, respectively ([@B26]; [@B40]). The *bla*~OXA-23~ gene has been reported in *A. baumannii* isolates worldwide and is mediated both by chromosomal integration and plasmids. The *bla*~OXA-24~ gene can also be localized to chromosomes or plasmids, appears to be less widespread than the *bla*~OXA-23~ gene, and is relatively rare in China ([@B25]). The chromosomally located *bla*~OXA-51-like~ gene is unique and naturally occurring in *A. baumannii*; thus, this gene is becoming an important genetic marker for the identification of organisms at the species level ([@B34],). The plasmid-mediated *bla*~OXA-58~ gene has been reported in *Acinetobacter* sp. from many countries around the world, but is rare in China.

In this research, we found that in all the 145 CRAB isolates, the co-occurrence of *bla*~OXA-51-like~ gene and *bla*~OXA-23~ gene could be detected in 134 isolates (92.3%). This result indicated that the plasmid-mediated transfer of *bla*~OXA-23~ gene might be the most common mechanism by which *A. baumannii* becomes carbapenem resistance in these two comprehensive military hospitals in Beijing. Although the *bla*~OXA-58~ gene and *bla*~OXA-24~ gene have been reported in many countries, but the prevalence of these two genes is relatively rare in China. That could be explained that only one isolate carried the *bla*~OXA-58~ gene and no *bla*~OXA-24~ gene was detected in the CRAB isolates. However, 10 isolates could detect none of the plasmid-mediated OXA-carbapenemase genes including *bla*~OXA-23,~ *bla*~OXA-24~ and *bla*~OXA-58,~ which indicated that these isolates might harbored other resistant genes such as MBLs against carbapenem. These data are consistent with other reports from China and other countries ([@B34]; [@B36]; [@B40]; [@B31]).

In the conventional PCR assay, the *bla*~OXA-51-like~ gene could not be amplified from seven clinical isolates. We thought that the low bacterial contents and incorrect pathogen identification may account for the failure to amplify these samples. Thus, the seven strains were analyzed for the presence of the *bla*~OXA-51-like~ gene by the LAMP method described here, yielding positive results in each case, which was confirmed using the Vitek 2 system. Our results showed that these clinical isolates were actually *A. baumannii*. These results suggest that occasionally the sensitivity of conventional PCR is not satisfactory and may introduce errors into diagnostic test results.

Compared with traditional methods for pathogen diagnosis, LAMP assays can generate results more easily and rapidly, with high sensitivity and specificity ([@B19]). The LAMP reaction does not require temperature cycling, with just a temperature-controlled water bath or a constant-temperature environment being sufficient. LAMP primers are designed to match four or six of the six or eight independent target-sequence regions, so the specificity and sensitivity are enhanced greatly. Under optimum conditions, the LAMP reaction can be completed in 1 h. In this study, we described a LAMP assay based on the *bla*~OXA-51-like~ gene for detecting *A. baumannii*. This LAMP method could detect the target DNA within 60 min at an isothermal temperature of 65°C. The detection limit of the LAMP assay was 50 pg/μl, which was about 10-fold greater than that of PCR. Furthermore, the LAMP method described here could distinguish *A. baumannii* from *A. nosocomialis* (genospecies 13TU), *A. pittii* (genospecies 3), and the *A. Baumannii* complex (*A. baumannii*, *A. nosocomialis*, *A. pittii*, and *A. calcoaceticus*). Previously, there were two reports on the use of an *A. baumannii* LAMP assay, based on targeting the 16S--23S rRNA intergenic spacer sequence ([@B29]) and the conserved regions of the *pga*D gene of *A. baumannii* ([@B35]). However, the former could not effectively distinguish *A. baumannii* from *A. nosocomialis*, and *A. pittii*, and the specificity of *A. baumannii* LAMP assay of the latter was only 75%.

Conclusion
==========

A rapid, sensitive, specific, and effective LAMP assay was established for the detection of *A. baumannii*. The LAMP assay will be very useful for the rapid detection of pathogens in clinical samples. Meanwhile, this report provides some therapeutic recommendations for the treatment of *A. baumannii* infection and a warning that the growing emergence of carbapenem-resistant *A. baumannii* has led to an inadequacy of therapeutic choices in treating MDR-AB infections among patients in China. Our findings further emphasize that when investigating outbreaks caused by carbapenem-resistant *A. baumannii*, both the detection of carbapenemase-associated genes and PFGE are needed.

Author Contributions
====================

Puyuan Li and Wenkai Niu wrote the main manuscript text. Puyuan Li, Huan Li, and Wei Liu prepared **Figures [1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"}**. Leijing Guo prepared **Figure [5](#F5){ref-type="fig"}**. Puyuan Li, Wenkai Niu, Hong Lei, Xiangna Zhao, Dayang Zou, Xin Yuan, and Huiying Liu executed the experiments. Changqing Bai and Jing Yuan helped conceive the project and designed the experiments. All authors reviewed the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This project was supported by the Beijing Natural Science Foundation (Grant No.7142118), a Translational Medicine Project from the Academy of Military Medical Science in 2013, Mega-projects of Science and Technology Research of China Grant 2013ZX10004-203, and Capital Characteristic Clinic project of Beijing (Z121107001012127).

We thank the 309th Hospital of PLA and Institute of Disease Control and Prevention, Academy of Military Medical Sciences for kindly providing clinical isolates and reference strains. We are grateful to Yin Xiuyun from the Department of Clinical Laboratory of the 307th Hospital of PLA for performing the collection of isolates. The analysis of PFGE by Wang Jian from the Institute of Disease Control and Prevention, Academy of Military Medical Sciences (Beijing, China) is gratefully appreciated. We also thank Wei Xiao, Cui Qian, Yang Zhan, Yan Xiabei, and Dong Derong for assistance during the course of this research.

[^1]: Edited by: *Alexandre Gonçalves, University of Trás-os-Montes e Alto Douro, Portugal*

[^2]: Reviewed by: *Ørjan Samuelsen, University Hospital of North Norway, Norway; Vishvanath Tiwari, Central University of Rajasthan, India; Paolo Landini, Università degli Studi di Milano, Italy*

[^3]: *^†^These authors have contributed equally to this work*.

[^4]: This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
